How ZYNLONTA Works | ZYNLONTA® (loncastuximab tesirine-lpyl) Patient Site

How ZYNLONTA®
Targets Cancer

ZYNLONTA® (loncastuximab tesirine-lpyl) is what’s
known as an antibody-drug conjugate (or ADC)

Antibody-Drug Conjugate — Also called ADC. A substance made up of a monoclonal antibody (also called mAb) that is chemically linked to a drug. The mAb binds to specific proteins found on certain types of cells, including cancer cells. The drug enters these cells and kills them. Some ADCs are used to treat cancer.

 

 

How ZYNLONTA®
Targets Cancer

ZYNLONTA® (loncastuximab tesirine-lpyl) is what’s
known as an antibody-drug conjugate (or ADC)

Antibody-Drug Conjugate — Also called ADC. A substance made up of a monoclonal antibody (also called mAb) that is chemically linked to a drug. The mAb binds to specific proteins found on certain types of cells, including cancer cells. The drug enters these cells and kills them. Some ADCs are used to treat cancer.

 

 
Not an actual patient.

ZYNLONTA® uses a “find, bind, and release” strategy
to target cancer cells

ZYNLONTA® is a targeted therapy that:

  • 1Finds and binds to the cancer cells
  • 2Releases cancer-killing therapy

ZYNLONTA® works by specifically targeting diffuse large B-cell lymphoma (DLBCL) cancer cells, and is different than
traditional chemotherapy.

Chemotherapy — Treatment to stop the growth of cancer cells by killing the cells or by stopping them from dividing. It may be given by mouth, injection, infusion, or on the skin, depending on the type and stage of the cancer being treated. It may be given alone or with other treatments.

 

 
  • 0

    ZYNLONTA® contains an antibody that is attached to an anti-cancer drug.

  • 1

    The antibody finds and binds to a specific area of the cancer cell called CD19.

    CD19 — A type of B-cell antigen that appears more than normal in B-cell related cancers.

     

     
  • 2

    The cancer cell absorbs ZYNLONTA®.

  • 3

    Once inside, ZYNLONTA® breaks apart and the anti-cancer drug is released.

  • 4

    This causes the cancer cell to die.

ZYNLONTA® antibody attached to anti-cancer drug
 
0

ZYNLONTA® contains an antibody that is attached to an anti-cancer drug.

ZYNLONTA® antibody attached to anti-cancer drug
1

The antibody finds and binds to
a specific area of the cancer cell
called CD19.

CD19 — A type of B-cell antigen that appears more than normal in B-cell related cancers.

 

 
CD19 in cancer cell
2

The cancer cell absorbs
ZYNLONTA®.

Antibody binding to CD19
3

Once inside, ZYNLONTA®
breaks apart and the anti-cancer
drug is released.

Cancer cell absorbing ZYNLONTA®
4

This causes the cancer cell
to die.

Cancer cell dies

ZYNLONTA® was specifically studied in adults who needed their next DLBCL therapy option after trying 2 or more past therapies

ZYNLONTA® is for people living with…

Relapsed cancer:

The cancer came back after past therapies worked

OR

Refractory cancer:

Therapy/therapies have not worked or no longer work

Ask your doctor if ZYNLONTA® is right for you.

Learn about
ZYNLONTA® results

Study results icon
Find results for ZYNLONTA®

Learn how
ZYNLONTA® is given

ZYNLONTA® infusions icon
Learn about ZYNLONTA® infusions
Expand

What is ZYNLONTA®?

Important Safety Information

ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

It is not known if ZYNLONTA® is safe and effective in children.

The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

Read full Important Safety Information

IMPORTANT SAFETY INFORMATION

What are the possible side effects of ZYNLONTA®?

ZYNLONTA® may cause serious side effects, including:

  • Fluid retention. Your body may hold too much fluid during treatment with ZYNLONTA®. This can be serious. Tell your healthcare provider if you develop new or worsening swelling or puffiness, weight gain, chest pain, shortness of breath, or trouble breathing
  • Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with ZYNLONTA® but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with ZYNLONTA®. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding
  • Read full Important Safety Information
  • Infections. Serious infections, including infections that can cause death, have happened in people treated with ZYNLONTA®. Tell your healthcare provider right away if you have new or worsening signs or symptoms of infection
  • Skin reactions. Serious skin reactions have happened in people treated with ZYNLONTA®. Tell your healthcare provider if you get new or worsening skin reactions, including sensitivity to sunlight, skin rash, peeling, redness or irritation. You may burn more easily or get severe sunburns

The most common side effects of ZYNLONTA® include:

  • feeling tired or weak
  • skin rash
  • swelling
  • nausea
  • muscle or joint pain
  • increase in blood sugar (hyperglycemia)
  • changes in certain blood or laboratory tests

ZYNLONTA® may cause fertility problems in males which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ZYNLONTA®.

What should I avoid while receiving ZYNLONTA®?

Avoid or limit your exposure to sunlight, including sunlight through glass, such as buildings or vehicle windows and artificial sunlight such as sunlamps or tanning beds. Exposure to sunlight during treatment with ZYNLONTA® can cause skin reaction or rash. Use sun protection measures such as sunscreen and wear loose-fitting clothes that cover your skin while out in sunlight.

Before you receive ZYNLONTA®, tell your healthcare provider about all of your medical conditions, including if you:

  • have an active infection or have had one recently
  • have liver problems
  • are pregnant or plan to become pregnant. ZYNLONTA® can harm your unborn baby

    Females who can become pregnant:

    • your healthcare provider may do a pregnancy test before starting treatment with ZYNLONTA®
    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 10 months after the last dose of ZYNLONTA®. Talk to your healthcare provider about effective birth control. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZYNLONTA®

    Males with female partners who can become pregnant:

    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 7 months after the last dose of ZYNLONTA®
  • are breastfeeding or plan to breastfeed. It is not known if ZYNLONTA® passes into breast milk. Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.

Please see the full Prescribing Information for ZYNLONTA®, including Patient Information, for additional Important Safety Information.

What is ZYNLONTA®?

Important Safety Information

ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

It is not known if ZYNLONTA® is safe and effective in children.

The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

Read full Important Safety Information

IMPORTANT SAFETY INFORMATION

What are the possible side effects of ZYNLONTA®?

ZYNLONTA® may cause serious side effects, including:

  • Fluid retention. Your body may hold too much fluid during treatment with ZYNLONTA®. This can be serious. Tell your healthcare provider if you develop new or worsening swelling or puffiness, weight gain, chest pain, shortness of breath, or trouble breathing
  • Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with ZYNLONTA® but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with ZYNLONTA®. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding
  • Read full Important Safety Information
  • Infections. Serious infections, including infections that can cause death, have happened in people treated with ZYNLONTA®. Tell your healthcare provider right away if you have new or worsening signs or symptoms of infection
  • Skin reactions. Serious skin reactions have happened in people treated with ZYNLONTA®. Tell your healthcare provider if you get new or worsening skin reactions, including sensitivity to sunlight, skin rash, peeling, redness or irritation. You may burn more easily or get severe sunburns

The most common side effects of ZYNLONTA® include:

  • feeling tired or weak
  • skin rash
  • swelling
  • nausea
  • muscle or joint pain
  • increase in blood sugar (hyperglycemia)
  • changes in certain blood or laboratory tests

ZYNLONTA® may cause fertility problems in males which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ZYNLONTA®.

What should I avoid while receiving ZYNLONTA®?

Avoid or limit your exposure to sunlight, including sunlight through glass, such as buildings or vehicle windows and artificial sunlight such as sunlamps or tanning beds. Exposure to sunlight during treatment with ZYNLONTA® can cause skin reaction or rash. Use sun protection measures such as sunscreen and wear loose-fitting clothes that cover your skin while out in sunlight.

Before you receive ZYNLONTA®, tell your healthcare provider about all of your medical conditions, including if you:

  • have an active infection or have had one recently
  • have liver problems
  • are pregnant or plan to become pregnant. ZYNLONTA® can harm your unborn baby

    Females who can become pregnant:

    • your healthcare provider may do a pregnancy test before starting treatment with ZYNLONTA®
    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 10 months after the last dose of ZYNLONTA®. Talk to your healthcare provider about effective birth control. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZYNLONTA®

    Males with female partners who can become pregnant:

    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 7 months after the last dose of ZYNLONTA®
  • are breastfeeding or plan to breastfeed. It is not known if ZYNLONTA® passes into breast milk. Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.

Please see the full Prescribing Information for ZYNLONTA®, including Patient Information, for additional Important Safety Information.